Genentech is a leading biotech company.  Our partnership with the hemophilia community began over 30 years ago when  we developed the first cloned, virus-free, nonblood-derived version of the factor VIII  protein.* Since then, we haven’t stopped working toward our goal of advancing  and improving treatment. But this partnership goes far beyond developing medicines. 

Genentech is committed to advancing all  aspects of life with hemophilia A, starting  with patient care. We strive to provide Treatment for All who need it, including  underserved communities around the globe. 

We Support the Person through education,  resources, and tools designed to help individuals thrive throughout their

treatment journey. 

We Connect the Community through active  engagements that help bring these individuals  together to learn and grow. 

Each day, we work alongside the community  to improve life with hemophilia A by creating  what’s next together.

*Genentech outlicensed worldwide production and  marketing of factor VIII.